Core Insights - Septerna, Inc. has granted an inducement award to its Chief Legal Officer, Mark A. Wilson, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company's 2026 Inducement Plan [1][2] Group 1: Stock Option Details - The stock option has an exercise price of $25.41 per share, which is equal to Septerna's closing share price on February 6, 2026 [2] - The stock option will vest over four years, with 25% of the shares vesting on the one-year anniversary and the remaining 75% vesting in equal monthly installments over 36 months, contingent on Mr. Wilson's continuous employment [2] Group 2: Company Overview - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, aiming to address significant unmet medical needs [3] - The company utilizes its proprietary Native Complex Platform to develop a diverse pipeline of novel oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases [3]
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)